The sterile injectable manufacturing site of a multi-national pharmaceutical company experienced a sudden and unexpected increase in units with visible crystals. Despite the drug being on the FDA drug shortage list, manufacturing was temporarily halted. Sufficient determination of the root cause of the crystallization with proposed countermeasures was required to restart manufacturing. The company brought skilled MetaExpert in to lead the charge.